Heron Therapeutics (HRTX) Research & Development (2010 - 2026)
Heron Therapeutics' (HRTX) quarterly Research & Development came in at $14.3 million in Q1 2026, up 16.22% YoY from $12.3 million in Q1 2025, and up 281.95% on a QoQ basis from $3.7 million in Q4 2025.
Heron Therapeutics (HRTX) Research & Development (2010 - 2026) Analysis & Trends
Heron Therapeutics (HRTX) has 17 years of Research & Development data on file, last reported at $14.3 million in Q1 2026.
- Quarterly Research & Development rose 16.22% year-over-year to $14.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $33.1 million (up 1676.65% YoY) and the FY2025 annual result came in at $12.4 million, down 25.5% from the prior year.
- Research & Development advanced to $14.3 million in Q1 2026, from $3.7 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $23.4 million in Q1 2022 to a low of -$19.3 million in Q4 2024.
- A 5-year average of $7.9 million and a median of $9.3 million in 2023 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2023 — Research & Development surged 188.46% — and 2024, when it sank 256.92%.
- Tracing HRTX's Research & Development over 5 years: stood at -$13.9 million in 2022, then surged by 188.46% to $12.3 million in 2023, then slumped by 256.92% to -$19.3 million in 2024, then soared by 119.36% to $3.7 million in 2025, then soared by 281.95% to $14.3 million in 2026.
- The last three Research & Development figures came in at $14.3 million (Q1 2026), $3.7 million (Q4 2025), and $3.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | Heron Therapeutics | 58.32 Mn | 15.65 Mn | 26.09 Mn | 14.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 14.16 Mn |
| Mar 31, 2026 | 14.31 Mn |
| Dec 31, 2025 | 3.75 Mn |
| Sep 30, 2025 | 3.47 Mn |
| Jun 30, 2025 | 11.58 Mn |
| Mar 31, 2025 | 12.31 Mn |
| Dec 31, 2024 | -19.35 Mn |
| Sep 30, 2024 | 4.47 Mn |
| Jun 30, 2024 | 4.43 Mn |
| Mar 31, 2024 | 4.61 Mn |
| Dec 31, 2023 | 12.33 Mn |
| Sep 30, 2023 | 9.29 Mn |
| Jun 30, 2023 | 13.21 Mn |
| Mar 31, 2023 | 8.84 Mn |
| Dec 31, 2022 | -13.94 Mn |
| Sep 30, 2022 | 18.38 Mn |
| Jun 30, 2022 | 22.94 Mn |
| Mar 31, 2022 | 23.42 Mn |
| Dec 31, 2021 | -14.77 Mn |
| Sep 30, 2021 | 28.60 Mn |